Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Ongoing challenges for pharmacotherapy for dyslipidemia|
|Citation:||Expert Opinion on Pharmacotherapy, 2015; 16(3):347-356|
|Publisher:||Taylor and Francis|
|Anthony D Pisaniello, Daniel J Scherer, Yu Kataoka and Stephen J Nicholls|
|Abstract:||Introduction: While increasing evidence has led to lipid-modifying therapy achieving an important role in the treatment guidelines for the prevention of cardiovascular disease, these agents are suboptimally used and there remains a considerable risk of clinical events. Accordingly, there is a need to develop more effective lipid-modifying approaches in many patients. Areas covered: A literature search was performed of topical manuscripts focusing on factors influencing use of established therapies and new agents in development that target a range of lipid factors. Expert opinion: More intensive efforts are required to ensure that statin use is maximized in higher risk patients. A range of novel therapies, including proprotein convertase subtilisin kexin-type 9 and cholesteryl ester transfer protein inhibitors, may provide additional protection, although this remains to be established by clinical trials.|
|Keywords:||Atherosclerosis; cardiovascular risk; lipid-modifying therapy; lipids|
|Rights:||© 2015 Informa UK, Ltd. ISSN 1465-6566, e-ISSN 1744-7666 All rights reserved: reproduction in whole or in part not permitted|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.